Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis

Vanessa Cecchin, Maria Elisabetta Zannin, Daniele Ferrari, Irene Pontikaki, Elisabetta Miserocchi, Maria P Paroli, Claudia Bracaglia, Denise Pires Marafon, Serena Pastore, Fulvio Parentin, Gabriele Simonini, Cinzia De Libero, Fernanda Falcini, Antonella Petaccia, Giovanni Filocamo, Riccardo De Marco, Francesco La Torre, Silvana Guerriero, Silvana Martino, Francesco ComacchioValentina Muratore, Giorgia Martini, Fabio Vittadello, Francesco Zulian

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years.

METHODS: Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent. Data recorded every 3 months were uveitis course, number/type of ocular flares and complications, drug-related adverse events (AE), and treatment switch or withdrawal. Data of patients treated for ≥ 2 years were analyzed by descriptive statistics.

RESULTS: Up to December 2014, 154 patients with ≥ 24 months followup were included in the study. Fifty-nine patients were treated with IFX and 95 with ADA. Clinical remission, defined as the absence of flares for > 6 months on treatment, was achieved in 69 patients (44.8%), with a better remission rate for ADA (60.0%) as compared to IFX (20.3%; p < 0.001). A significant reduction of flares was observed in all patients without difference between the 2 treatment modalities. The number of new ocular complications decreased in both groups but was lower for ADA (p = 0.015). No serious AE were recorded; 16.4% of patients experienced 35 minor AE and the incidence rate was lower with ADA than with IFX.

CONCLUSION: At the 2-year followup, ADA showed a better efficacy and safety profile than IFX for the treatment of refractory JIA-associated uveitis.

Original languageEnglish
Pages (from-to)1167-1172
Number of pages6
JournalJournal of Rheumatology
Volume45
Issue number8
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Juvenile Arthritis
Uveitis
Safety
Therapeutics
Adalimumab
Infliximab
Immunosuppressive Agents
Drug-Related Side Effects and Adverse Reactions
Registries
Adrenal Cortex Hormones
Incidence

Cite this

Cecchin, V., Zannin, M. E., Ferrari, D., Pontikaki, I., Miserocchi, E., Paroli, M. P., ... Zulian, F. (2018). Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 45(8), 1167-1172. https://doi.org/10.3899/jrheum.171006

Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. / Cecchin, Vanessa; Zannin, Maria Elisabetta; Ferrari, Daniele; Pontikaki, Irene; Miserocchi, Elisabetta; Paroli, Maria P; Bracaglia, Claudia; Marafon, Denise Pires; Pastore, Serena; Parentin, Fulvio; Simonini, Gabriele; De Libero, Cinzia; Falcini, Fernanda; Petaccia, Antonella; Filocamo, Giovanni; De Marco, Riccardo; La Torre, Francesco; Guerriero, Silvana; Martino, Silvana; Comacchio, Francesco; Muratore, Valentina; Martini, Giorgia; Vittadello, Fabio; Zulian, Francesco.

In: Journal of Rheumatology, Vol. 45, No. 8, 01.08.2018, p. 1167-1172.

Research output: Contribution to journalArticle

Cecchin, V, Zannin, ME, Ferrari, D, Pontikaki, I, Miserocchi, E, Paroli, MP, Bracaglia, C, Marafon, DP, Pastore, S, Parentin, F, Simonini, G, De Libero, C, Falcini, F, Petaccia, A, Filocamo, G, De Marco, R, La Torre, F, Guerriero, S, Martino, S, Comacchio, F, Muratore, V, Martini, G, Vittadello, F & Zulian, F 2018, 'Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis', Journal of Rheumatology, vol. 45, no. 8, pp. 1167-1172. https://doi.org/10.3899/jrheum.171006
Cecchin, Vanessa ; Zannin, Maria Elisabetta ; Ferrari, Daniele ; Pontikaki, Irene ; Miserocchi, Elisabetta ; Paroli, Maria P ; Bracaglia, Claudia ; Marafon, Denise Pires ; Pastore, Serena ; Parentin, Fulvio ; Simonini, Gabriele ; De Libero, Cinzia ; Falcini, Fernanda ; Petaccia, Antonella ; Filocamo, Giovanni ; De Marco, Riccardo ; La Torre, Francesco ; Guerriero, Silvana ; Martino, Silvana ; Comacchio, Francesco ; Muratore, Valentina ; Martini, Giorgia ; Vittadello, Fabio ; Zulian, Francesco. / Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. In: Journal of Rheumatology. 2018 ; Vol. 45, No. 8. pp. 1167-1172.
@article{5b7e4890bd3c4a78bc75dbb5dfd51620,
title = "Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis",
abstract = "OBJECTIVE: Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years.METHODS: Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent. Data recorded every 3 months were uveitis course, number/type of ocular flares and complications, drug-related adverse events (AE), and treatment switch or withdrawal. Data of patients treated for ≥ 2 years were analyzed by descriptive statistics.RESULTS: Up to December 2014, 154 patients with ≥ 24 months followup were included in the study. Fifty-nine patients were treated with IFX and 95 with ADA. Clinical remission, defined as the absence of flares for > 6 months on treatment, was achieved in 69 patients (44.8{\%}), with a better remission rate for ADA (60.0{\%}) as compared to IFX (20.3{\%}; p < 0.001). A significant reduction of flares was observed in all patients without difference between the 2 treatment modalities. The number of new ocular complications decreased in both groups but was lower for ADA (p = 0.015). No serious AE were recorded; 16.4{\%} of patients experienced 35 minor AE and the incidence rate was lower with ADA than with IFX.CONCLUSION: At the 2-year followup, ADA showed a better efficacy and safety profile than IFX for the treatment of refractory JIA-associated uveitis.",
author = "Vanessa Cecchin and Zannin, {Maria Elisabetta} and Daniele Ferrari and Irene Pontikaki and Elisabetta Miserocchi and Paroli, {Maria P} and Claudia Bracaglia and Marafon, {Denise Pires} and Serena Pastore and Fulvio Parentin and Gabriele Simonini and {De Libero}, Cinzia and Fernanda Falcini and Antonella Petaccia and Giovanni Filocamo and {De Marco}, Riccardo and {La Torre}, Francesco and Silvana Guerriero and Silvana Martino and Francesco Comacchio and Valentina Muratore and Giorgia Martini and Fabio Vittadello and Francesco Zulian",
year = "2018",
month = "8",
day = "1",
doi = "10.3899/jrheum.171006",
language = "English",
volume = "45",
pages = "1167--1172",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "8",

}

TY - JOUR

T1 - Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis

AU - Cecchin, Vanessa

AU - Zannin, Maria Elisabetta

AU - Ferrari, Daniele

AU - Pontikaki, Irene

AU - Miserocchi, Elisabetta

AU - Paroli, Maria P

AU - Bracaglia, Claudia

AU - Marafon, Denise Pires

AU - Pastore, Serena

AU - Parentin, Fulvio

AU - Simonini, Gabriele

AU - De Libero, Cinzia

AU - Falcini, Fernanda

AU - Petaccia, Antonella

AU - Filocamo, Giovanni

AU - De Marco, Riccardo

AU - La Torre, Francesco

AU - Guerriero, Silvana

AU - Martino, Silvana

AU - Comacchio, Francesco

AU - Muratore, Valentina

AU - Martini, Giorgia

AU - Vittadello, Fabio

AU - Zulian, Francesco

PY - 2018/8/1

Y1 - 2018/8/1

N2 - OBJECTIVE: Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years.METHODS: Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent. Data recorded every 3 months were uveitis course, number/type of ocular flares and complications, drug-related adverse events (AE), and treatment switch or withdrawal. Data of patients treated for ≥ 2 years were analyzed by descriptive statistics.RESULTS: Up to December 2014, 154 patients with ≥ 24 months followup were included in the study. Fifty-nine patients were treated with IFX and 95 with ADA. Clinical remission, defined as the absence of flares for > 6 months on treatment, was achieved in 69 patients (44.8%), with a better remission rate for ADA (60.0%) as compared to IFX (20.3%; p < 0.001). A significant reduction of flares was observed in all patients without difference between the 2 treatment modalities. The number of new ocular complications decreased in both groups but was lower for ADA (p = 0.015). No serious AE were recorded; 16.4% of patients experienced 35 minor AE and the incidence rate was lower with ADA than with IFX.CONCLUSION: At the 2-year followup, ADA showed a better efficacy and safety profile than IFX for the treatment of refractory JIA-associated uveitis.

AB - OBJECTIVE: Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years.METHODS: Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent. Data recorded every 3 months were uveitis course, number/type of ocular flares and complications, drug-related adverse events (AE), and treatment switch or withdrawal. Data of patients treated for ≥ 2 years were analyzed by descriptive statistics.RESULTS: Up to December 2014, 154 patients with ≥ 24 months followup were included in the study. Fifty-nine patients were treated with IFX and 95 with ADA. Clinical remission, defined as the absence of flares for > 6 months on treatment, was achieved in 69 patients (44.8%), with a better remission rate for ADA (60.0%) as compared to IFX (20.3%; p < 0.001). A significant reduction of flares was observed in all patients without difference between the 2 treatment modalities. The number of new ocular complications decreased in both groups but was lower for ADA (p = 0.015). No serious AE were recorded; 16.4% of patients experienced 35 minor AE and the incidence rate was lower with ADA than with IFX.CONCLUSION: At the 2-year followup, ADA showed a better efficacy and safety profile than IFX for the treatment of refractory JIA-associated uveitis.

U2 - 10.3899/jrheum.171006

DO - 10.3899/jrheum.171006

M3 - Article

C2 - 29657140

VL - 45

SP - 1167

EP - 1172

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 8

ER -